---
title: "Lilly Endowment Has Sold $111.8B in LLY Stock — But It's Not a Bearish Signal"
type: news
slug: lilly-endowment-systematic-diversification-111b
canonical_url: https://13finsight.com/news/lilly-endowment-systematic-diversification-111b
published_at: 2026-03-15T03:03:24.913Z
updated_at: 2026-03-23T07:02:24.290Z
author: Sarah Mitchell
author_title: Education Editor
author_url: https://13finsight.com/authors/sarah-mitchell
word_count: 452
locale: en
source: 13F Insight
---

# Lilly Endowment Has Sold $111.8B in LLY Stock — But It's Not a Bearish Signal

> The Lilly Endowment, one of America's largest charitable foundations, has systematically sold over $111 billion in Eli Lilly shares since 2003. This is not insider pessimism—it's foundation law in action.

The Lilly Endowment Inc has sold $111.8 billion in Eli Lilly stock since 2003—making it one of the largest systematic sell programs in SEC filing history. Yet this is not a bearish signal. It’s foundation law. The Scale of the Sell Program The Lilly Endowment, one of America’s largest charitable foundations with assets exceeding $14 billion, has executed 10,747 Form 4 transactions in Eli Lilly stock over 22 years. The endowment still holds 92.2 million shares—a 10%+ beneficial ownership stake—but the sheer volume of sales requires explanation. Recent activity shows the pattern continues: in late November 2025, the endowment sold shares across 20+ separate Form 4 filings, each at prices between $1,082 and $1,110 per share. In December 2025, sales continued, with the most recent transaction on December 29, 2025, at $1,085.04 per share. Why Foundations Must Diversify The Lilly Endowment inherited its massive LLY stake from the Lilly family’s founding ownership. Federal law and foundation governance rules require endowments to: Diversify holdings to reduce concentration risk and ensure long-term stability Maintain prudent asset allocation across multiple sectors and asset classes Distribute 5% annually to charitable causes (required by tax law) Avoid over-reliance on a single security that could jeopardize the foundation’s mission The Lilly Endowment’s systematic selling is not a vote of no-confidence in Eli Lilly. It’s a fiduciary obligation to rebalance a portfolio that would otherwise be dangerously concentrated in a single stock. The Endowment Remains a Major Shareholder Despite $111.8 billion in cumulative sales, the Lilly Endowment remains one of Eli Lilly’s largest shareholders. The endowment’s 92.2 million shares represent approximately 6.5% of the company’s outstanding equity—a position that would take decades to fully liquidate at current selling rates. This is the key distinction: the endowment is not exiting its position. It is slowly, methodically rebalancing a legacy holding to fund its charitable mission while maintaining a significant stake in the company its founder built. What to Watch Endowment distribution rate—If the Lilly Endowment increases its annual charitable distributions, LLY sales may accelerate to fund those commitments Eli Lilly stock price—The endowment appears to use price-based triggers for sales; higher prices may trigger larger tranches Sector rotation—Monitor the endowment’s 13F filings to see which sectors it is rotating proceeds into (healthcare, technology, fixed income) Remaining LLY stake—At current selling rates, the endowment will hold a meaningful LLY position for at least another 20+ years Key Facts Metric Value Total LLY Sales (Career) $111.8 billion Total Transactions 10,747 Current LLY Holdings 92.2 million shares Beneficial Ownership % ~6.5% of LLY First Transaction July 31, 2003 Most Recent Transaction December 29, 2025 Endowment Total Assets $14+ billion For the full transaction history and insider profile, visit the Lilly Endowment profile page.

---

Source: 13F Insight — https://13finsight.com/news/lilly-endowment-systematic-diversification-111b
Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell
Last updated: 2026-03-23T07:02:24.290Z